Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?
Xconomy
JUNE 13, 2019
The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. One, headed for Phase 2 testing by next year, is being developed for mood or anxiety disorders.
Let's personalize your content